Published in Int J Radiat Oncol Biol Phys on September 01, 1979
Analysis of growth delay data: potential pitfalls. Br J Cancer Suppl (1980) 0.96
The uptake of 3H-vincristine by a mouse carcinoma during a course of fractionated radiotherapy. Br J Cancer (1989) 0.75
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 7.50
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol (1998) 7.26
More on managing metastatic choroidal tumors. Oncology (Williston Park) (1989) 5.12
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys (1995) 3.32
A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry (1985) 2.72
Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2000) 2.68
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
Carcinoma of the cervix: predictive value of clinical and magnetic resonance (MR) imaging assessment of prognostic factors. Int J Radiat Oncol Biol Phys (1993) 2.13
Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res (1993) 1.99
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol (1995) 1.96
Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys (1997) 1.93
Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.83
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
Demonstration of radiosensitization of hypoxic cells in solid tumours by metronidazole. Br J Radiol (1974) 1.77
Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg (1994) 1.72
Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys (1995) 1.71
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys (1998) 1.71
Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int J Radiat Oncol Biol Phys (1994) 1.70
Uveal melanoma. Growth rate and prognosis. Arch Ophthalmol (1997) 1.67
Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am (1998) 1.63
A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys (1991) 1.63
Transport of membrane-bound macromolecules by M cells in follicle-associated epithelium of rabbit Peyer's patch. Cell Tissue Res (1987) 1.59
RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys (1995) 1.57
High-dose-rate versus low-dose-rate intracavitary brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys (1990) 1.56
Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlorobimane: some applications to radiation and drug resistance in vitro and in vivo. Cancer Res (1986) 1.54
Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys (1999) 1.50
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2001) 1.50
Local control after the use of adjuvant electron beam intraoperative radiotherapy in patients with high-risk head and neck cancer: the UCSF experience. Cancer J Sci Am (2006) 1.48
Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry (1995) 1.47
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer (1988) 1.44
Failure of preenucleation radiation to decrease uveal melanoma mortality. Am J Ophthalmol (1988) 1.42
Mandibular reconstruction using a titanium plate: the impact of radiation therapy on plate preservation. Int J Radiat Oncol Biol Phys (1995) 1.41
Vision following helium ion radiotherapy of uveal melanoma: a Northern California Oncology Group study. Int J Radiat Oncol Biol Phys (1988) 1.39
Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys (1998) 1.38
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys (1994) 1.34
A Carboniferous insect gall: insight into early ecologic history of the Holometabola. Proc Natl Acad Sci U S A (1996) 1.34
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer (2000) 1.31
The neurotoxicity of misonidazole: pooling of data from five centres. Br J Radiol (1978) 1.31
Desmoid tumors--treatment and prognosis. Radiology (1977) 1.26
Economic evaluation of interventions to reduce road traffic injuries--a review of the literature with applications to low and middle-income countries. Asia Pac J Public Health (2004) 1.26
Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer (1982) 1.24
Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery (1995) 1.21
An ultrastructural study of the development of radiation injury in the lung. Radiology (1966) 1.21
Lymph node metastasis in maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys (2000) 1.20
Noggin and retinoic acid transform the identity of avian facial prominences. Nature (2002) 1.20
Hypoxia in head and neck cancer: how much, how important? Head Neck (2005) 1.20
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst (1997) 1.19
Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys (2000) 1.18
Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys (1983) 1.17
Kidney cell proliferation after unilateral nephrectomy as related to age. Cancer Res (1967) 1.16
Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res (1980) 1.16
Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer (1975) 1.15
Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol (1999) 1.14
Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery (1998) 1.14
Malignant tumors of the testis: analysis of treatment results and sites and causes of failure. Cancer (1977) 1.14
Radiation retinopathy. Int J Radiat Oncol Biol Phys (1979) 1.12
The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Br J Radiol (1980) 1.12
Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer (1981) 1.11
Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys (1999) 1.11
Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck (1998) 1.10
Biological properties and response to x-rays of first-generation transplants of spontaneous mammary carcinomas in C3H mice. Int J Radiat Biol Relat Stud Phys Chem Med (1975) 1.09
Radiation response of artificial pulmonary metastases of the EMT6 tumor. Int J Radiat Oncol Biol Phys (1976) 1.08
Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res (1994) 1.08
Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys (1994) 1.07
High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys (1993) 1.07
Stereotaxic irradiation of brain tumors. Cancer (1990) 1.07
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys (1979) 1.06
What is appropriate therapy for a patient with a single brain metastasis? Int J Radiat Oncol Biol Phys (1994) 1.06
The incidence of lung metastases in C3H mice after treatment of implanted solid tumours with x-rays or surgery. Br J Cancer (1974) 1.05
Prognostic factors in adult soft-tissue sarcomas of the head and neck. Int J Radiat Oncol Biol Phys (1997) 1.05
Control of retinoic acid synthesis and FGF expression in the nasal pit is required to pattern the craniofacial skeleton. Dev Biol (2004) 1.05
Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer (1977) 1.05
Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin Trials (1981) 1.04
Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys (2001) 1.04
Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer (1976) 1.04
Time-dose relationships in the mouse esophagus. Radiology (1974) 1.03
Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys (1989) 1.03
Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys (1996) 1.02
Radiation pneumonitis: a new approach to the derivation of time-dose factors. Cancer (1973) 1.02
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol (2003) 1.02
Glutathione depletion in tissues after administration of buthionine sulphoximine. Int J Radiat Oncol Biol Phys (1984) 1.02
Neon ion radiotherapy: results of the phase I/II clinical trial. Int J Radiat Oncol Biol Phys (1991) 1.02
Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol (1996) 1.02
Radiation tolerance of the spinal cord. Cancer (1975) 1.01
Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer (2002) 1.00
Elevated IGA in carcinoma of the nasopharynx. Cancer (1975) 1.00
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2001) 1.00
Should asymptomatic patients with inoperable bronchogenic carcinoma receive immediate radiotherapy? Yes. Am Rev Respir Dis (1978) 0.99
High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys (1992) 0.99
The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! Int J Radiat Oncol Biol Phys (1995) 0.99